

FAX TO BANK'S APOTHECARY: 215-357-2129

HEALTH PARTNER PLANS PRIOR AUTHORIZATION REQUEST FORM

DEFERASIROX - (Exjade® and Jadenu®)

Phone: 215-991-4300

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drugs, labs) left blank, illegible or not attached WILL delay the review process

| , | , , , , | |
|---|--|--|
| Patient Name: | Prescriber Name: | |
| HPP Member Number: | Fax: Phone: | |
| Date of Birth: | Office Contact: | |
| Address: | NPI: Promise ID: | |
| City, State ZIP: | Prescriber PA PROMISe ID: | |
| Patient Primary Phone: | Address: | |
| Line of Business: | | |
| ☐ CHIP | City, State ZIP: | |
| | Specialty/facility name (if applicable): | |
| | ☐ Expedited/Urgent | |
| Drug name: | | |
| Strength: | | |
| Days Supply: Number of Refills: | | |
| Directions / SIG: | | |
| HPP's maximum approval time is | 12 months but may be less depending on the drug. | |
| Please attach any pertinent medical history including labs | and information for this member that may support approval. | |
| Please answer the following questions and sign. | | |
| Q1. Does the patient have a diagnosis of transfusion iron overload, and have transfusion of greater than or equal to 100 mL/kg of | | |
| packed red blood cells [greater than or equal to 20 units for a 40 kg individual] and serum ferritin consistently >1000 mcg/L? | | |
| ☐Yes ☐ No | | |
| Q2. Is the patient 2 years of age or older? | | |
| Yes No | | |
| ☐ Yes ☐ No | | |
| Q3. Does the patient have a diagnosis of chronic iron overload with non-transfusion dependent thalassemia syndromes | | |
| with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L? | | |
| ☐ Yes ☐ No | | |
| Q4.Is the patient 10 years of age or older? | | |
| ☐ Yes ☐ No | | |
| | | |
| Q5.For transfusional iron overload, have the following lab results been attached? a. Serum ferritin level b. Serum creatinine and determine the creatinine clearance c. Serum transaminases and bilirubin d. Baseline auditory and ophthalmic examinations | | |
| ☐ Yes ☐ No | and optimization of the second | |
| Q6. For chronic iron overload with non-transfusion dependent thalassemia syndromes, have the following lab results been attached? a. Serum ferritin level on at least 2 measurements one month apart b. Serum creatinine and determine the creatinine clearance c. Serum transaminases and bilirubin d. Baseline auditory and ophthalmic examinations e. LIC by liver biopsy or by an FDA-cleared or approved method for identifying patients for treatment with deferasirox therapy Yes No | | |

This telecopy transmission confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have receive this telecopy in error, please notify the sender to arrange for the return of this document.



FAX TO BANK'S APOTHECARY: 215-357-2129

HEALTH PARTNER PLANS PRIOR AUTHORIZATION REQUEST FORM

DEFERASIROX – (Exjade® and Jadenu®)

Phone: 215-991-4300

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drugs, labs) left blank, illegible or not attached WILL delay the review process

| Patient Name: | Prescriber Name: | |
|-----------------------------|------------------|--|
| Q7. Requested Duration: | | |
| 2 Months | | |
| Q8. Additional Information: | | |
| | | |
| | | |
| | | |
| Prescriber Signature | Date | |

Updated 2018

FAX TO BANK'S APOTHECARY: 215-357-2129